Skip to content

Cullinan Therapeutics

US · CGEM #3243 by market cap Listed 2021
8.89 -0.18 -1.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:38

Price chart

Pre-market 8.82 -2.76%
After-hours 8.96 +0.79%
Overnight 8.97 -1.10%
22.958.898.892026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CGEM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -28.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 12.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -358.7% Better than 4%
Net margin -346.1% Better than 4%
Return on equity -44.0% Better than 10%
Return on invested capital -48.2% Better than 6%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -59.0% Better than 3%
6-month return -35.8% Better than 14%
12-month return (ex latest month) 57.6% Better than 87%
Distance below 52-week high 61.7% Better than 10%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.2x Better than 94%
Debt to assets 0.6% Better than 95%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 282.5% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -13.52%
1M -40.05%
3M -58.42%
6M -37.96%
YTD -14.11%
1Y +1.95%
3Y +1.48%
5Y -54.34%

Key statistics

Price & volume

Prev close
9.07
Open
8.84
Day range
8.80 - 9.46
Avg price
8.96
Volume
1.01M
Turnover
9.06M
Amplitude
7.22%
52-week range
8.47 - 23.19

Valuation

P/E
-2.65
P/E (TTM)
-2.88
P/B
2.05
EPS
-3.36
Net profit
-218.13M
Net assets
281.30M

Share structure

Market cap
577.15M
Float cap
433.63M
Shares out
64.92M
Float shares
48.78M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-01-08
52-week range 3% of range
8.47 23.19

61.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.48M net over the window

Short interest

Shares short
7.93M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Cullinan Therapeutics (CGEM)?

Cullinan Therapeutics last traded at 8.89. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Cullinan Therapeutics's market cap?

About 577.15M.

What is the P/E ratio of Cullinan Therapeutics?

The trailing twelve-month P/E is -2.88. The Valuation tab shows it against the stock's own five-year range.

Does Cullinan Therapeutics pay a dividend?

Cullinan Therapeutics does not currently pay a regular dividend.

Is Cullinan Therapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 34.00, which implies 282.5% upside from the current price. This is not investment advice.

What is Cullinan Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Cullinan Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:38:37 · For reference only, not investment advice and not tailored to your situation.

Cullinan Therapeutics discussion 0 comments

Add a comment